You are here

CV Sciences, Inc. to be a Featured Panelist at TheStreet’s Investing Event on October 13th in New York, NY

LAS VEGAS, Oct. 11, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our,” “us” or “we”), preeminent supplier and manufacturer of phytocannabinoids including industry-leading brand, PlusCBD Oil, is pleased to announce that it will be a featured panelist at Invest Like the Pros: TheStreet’s Boot Camp for Investors, to be held on October 13, 2018 in New York City. Attendees will learn from prominent experts on various topics ranging from short-term trading strategies to the current state of the cannabis industry to the future of big tech, and more.

CV Sciences’ Chief Executive Officer, Joseph Dowling, will be on a panel entitled, “How to Play the Fast-Emerging Cannabis Industry,” where experts will discuss the state of the industry, future direction and how investors can profit. Mr. Dowling will highlight how CV Sciences has led the hemp CBD industry with its commitment to transparency, quality products, and strong operational and financial performance.

“We are pleased to participate in TheStreet’s investing conference,” stated Mr. Dowling. “The CBD industry is an exciting investment opportunity with numerous new product categories and emerging vertical markets all gaining strong momentum. We embrace our industry position as we continually strive to provide leadership and credibility to one of the fastest growing industries.”

“Investors are seeking credible information about how they can profit from the cannabis industry,” said James R. Freiman, TheStreet’s SVP of Media Revenue. “Our events bring together experts from a variety of sectors, such as Mr. Dowling, in order to educate investors and give them actionable trading advice.”

To learn more about the event, visit TheStreet’s Boot Camp for Investors.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

ir@cvsi.com

866-976-4784

Thursday, October 11, 2018 - 15:07

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations